Pharmacoeconomic Guidelines: Austria

Country/Region: Austria
Published PE Recommendations
Guidelines on Health Economic Evaluations (Concensus Paper 2006)
PDF in EnglishPDF in German
Additional Information:
A working manual for the decision making process after an application to be listed on the positive list EKO

Information current as of Tuesday, January 21, 2020

Key Features

Type of Guidelines Published PE Recommendations
Title and year of the document Guidelines on Health Economic Evaluations (Concensus Paper 2006)
Affiliation of authors Institute for Pharmaeconomic Research (IPF) in cooperation with an expert group
Purpose of the document Providing recommendations for C/E studies and ensure a minimum standard of methodology and transparency
Standard reporting format included No
Disclosure Yes
Target audience of funding/ author's interests Decision makers
Perspective Apart from the societal perspective, other perspectives (e.g. health care system, social insurance,..) are possible
Indication Yes
Target population Be clearly specify
Subgroup analysis Yes
Choice of comparator Standard therapy, most frequent therapy or most effective therapy
Time horizon Depends on research question
Assumptions required Yes
Preferred analytical technique CMA, CEA, CUA
Costs to be included Costs relevant to the chosen perspective. Report indirect costs separately.
Source of costs Latest unit prices, give references.
Modeling Yes, requires details
Systematic review of evidences Not stated
Preference for effectiveness over efficacy Both acceptable
Preferred outcome measure Depends on research question
Preferred method to derive utility Should justify the selection
Equity issues stated Yes
Discounting costs 5%; SA:(3%-10%)
Discounting outcomes 5%; SA:(3%-10%)
Sensitivity analysis-parameters and range All key uncertain parameters, within a defined area, or probabilistic
Sensitivity analysis-methods One-way, multi-way, may be probabilistic analysis
Presenting results Must be reproduced transparently in disaggregated and aggregated form as for publication in peer reviewed journals
Incremental analysis Yes
Total costs vs effectiveness (cost/effectiveness ratio) Yes
Portability of results (Generalizability) Yes; Studies must refer to the national context
Financial impact analysis Possible
Mandatory or recommended or voluntary Recommended


Dr. Gottfried Endel, Head of HTA Department, Main Association of Austrian Social Security Institutions contributed to the key feature form.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now